Европска Унија - Бугарски - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Европска Унија - Бугарски - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - Гликогенна складова болест тип ii - Други стомашно-чревния тракт и обмяната на веществата средства, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Европска Унија - Бугарски - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - Други стомашно-чревния тракт и обмяната на веществата средства, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Европска Унија - Бугарски - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Европска Унија - Бугарски - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - Имуносупресори - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

Европска Унија - Бугарски - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - Хемофилия Б - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Европска Унија - Бугарски - EMA (European Medicines Agency)

dynavax gmbh - повърхностен антиген на хепатит В - Хепатит Б - Ваксини - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Бугарска - Бугарски - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - Морфин - 10 mg modified - release tablets

Бугарска - Бугарски - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - Морфин - 30 mg modified - release tablets

Бугарска - Бугарски - Изпълнителна агенция по лекарствата

mundipharma gesellschaft m.b.h. - Морфин - 60 mg modified - release tablets